Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and feasibility of
administering an allogeneic GM-CSF-secreting lethally irradiated whole melanoma cell vaccine
("melanoma GVAX"), alone or in combination with low dose cyclophosphamide (CPM), for the
adjuvant treatment of patients with surgically resected stage IIB-IV melanoma. Secondarily,
the investigators will assess in vitro correlates of anti-melanoma immunization by melanoma
GVAX, including serological and cellular immune responses in patients treated with either the
vaccine alone or the vaccine given with low dose CPM.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins